## Han Liu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2405075/publications.pdf

Version: 2024-02-01

516710 501196 30 911 16 28 citations h-index g-index papers 32 32 32 1617 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature, 2010, 467, 343-346.	27.8	123
2	Bimodal degradation of MLL by SCF <sup>Skp2</sup> and APC <sup>Cdc20</sup> assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes and Development, 2007, 21, 2385-2398.	5.9	97
3	MLL fusions: Pathways to leukemia. Cancer Biology and Therapy, 2009, 8, 1204-1211.	3.4	92
4	Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica, 2018, 103, 679-687.	3.5	67
5	î"Np63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. Cell Reports, 2017, 21, 2926-2939.	6.4	61
6	Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation. Autophagy, 2015, 11, 2160-2171.	9.1	58
7	Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2180-2185.	7.1	57
8	Cancer Cell Derived Small Extracellular Vesicles Contribute to Recipient Cell Metastasis Through Promoting HGF/c-Met Pathway*. Molecular and Cellular Proteomics, 2019, 18, 1619-1629.	3.8	44
9	Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4. Cancer Cell, 2014, 25, 530-542.	16.8	40
10	TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. Leukemia, 2018, 32, 2012-2016.	7.2	37
11	Local release of gemcitabine via <i>in situ</i> UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma. Drug Delivery, 2018, 25, 1642-1651.	5.7	37
12	Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixedâ€lineage leukemia. Cancer Science, 2020, 111, 1279-1290.	3.9	28
13	Biphasic MLL takes helm at cell cycle control: Implications in human mixed lineage leukemia. Cell Cycle, 2008, 7, 428-435.	2.6	27
14	Arsenic sulfide induces RAG1-dependent DNA damage for cell killing by inhibiting NFATc3 in gastric cancer cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 487.	8.6	27
15	Analysis of the genetic architecture of susceptibility to cervical cancer indicates that common SNPs explain a large proportion of the heritability. Carcinogenesis, 2015, 36, 992-998.	2.8	24
16	Environmental exposure to triclosan and polycystic ovary syndrome: a cross-sectional study in China. BMJ Open, 2018, 8, e019707.	1.9	19
17	Accelerated fabrication of antibacterial and osteoinductive electrospun fibrous scaffolds <i>via</i> electrochemical deposition. RSC Advances, 2018, 8, 9546-9554.	3.6	17
18	Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. British Journal of Cancer, 2021, 124, 770-776.	6.4	16

#	Article	IF	Citations
19	Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia. Leukemia, 2020, 34, 2484-2488.	7.2	15
20	Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors. Oncogene, 2020, 39, 5888-5901.	5.9	6
21	Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia. Leukemia, 2019, 33, 2951-2956.	7.2	5
22	MLL is required for miRNA-mediated translational repression. Cell Discovery, 2019, 5, 43.	6.7	3
23	Deubiquitinating enzyme inhibitor alleviates cyclin A1â€mediated proteasome inhibitor tolerance in mixedâ€lineage leukemia. Cancer Science, 2021, 112, 2287-2298.	3.9	3
24	mTORC1â€mediated amino acid signaling is critical for cell fate determination under transplantâ€induced stress. FEBS Letters, 2021, 595, 462-475.	2.8	2
25	A T-cell independent universal cellular therapy strategy through antigen depletion. Theranostics, 2022, 12, 1148-1160.	10.0	2
26	Targeting matrix metallopeptidase 2 by hydroxyurea selectively kills acute myeloid mixed-lineage leukemia. Cell Death Discovery, 2022, 8, 180.	4.7	2
27	USP47 Is a New Target in Chronic Myelogenous Leukemia. Blood, 2015, 126, 1572-1572.	1.4	1
28	Mixed-lineage leukemia protein modulates the loading of <i>let-7a</i> onto AGO1 by recruiting RAN. Haematologica, 2021, 106, 1995-1999.	3.5	1
29	The Association Between SERPINC1 C.883G>a and VT in the Chinese Population. Blood, 2015, 126, 3505-3505.	1.4	0
30	Novel Association of a F11 Variant with Venous Thromboembolism in a Chinese Han Population. Blood, 2015, 126, 3533-3533.	1.4	0